Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

September 30, 2027

Study Completion Date

March 31, 2028

Conditions
Total Knee ReplacementKnee Arthroplasty
Interventions
DRUG

Bupivacaine-Liposomal Bupivacaine

Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block

DRUG

Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate

Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.

Trial Locations (2)

06520

RECRUITING

Yale New Haven Hospital Saint Raphael Campus, New Haven

RECRUITING

Yale New Haven Hospital York Street Campus, New Haven

All Listed Sponsors
collaborator

Department of Anesthesiology Faculty Development Fund

UNKNOWN

lead

Yale University

OTHER